60427-77-2

Usage

InChI:InChI=1/C13H14O5/c1-9(13(15)16)7-12(14)18-8-10-3-5-11(17-2)6-4-10/h3-6H,1,7-8H2,2H3,(H,15,16)

Upstream product

• 104249-08-3 itaconic anhydride 
• 105-13-5 4-Methoxybenzyl alcohol 
• 2170-03-8 itaconic acid anhydride 

Downstream Products

• 1234694-20-2 C₇₅ 
• 1234694-20-2 cis-tetrahydro-3-methylene-2-oxo-5-n-octyl-4-furancarboxylic acid 
• 143225-27-8 1-benzyl-4-(4-methoxybenzyl)itaconate 
• 778649-16-4 2-methyl-4-methylene-5-oxotetrahydrofuran-3-carboxylic acid 

Relevant academic research and scientific papers

In situ proteome profiling of C75, a covalent bioactive compound with potential anticancer activities

A library of cell-permeable, minimally tagged C75 analogues was synthesized and used to uncover biological targets in human liver cancer cells. Known targets of C75, namely FASN and CPT1A, together with other unknown targets, including PDIA3, TFRC, and GAPDH, were thus identified.

INHIBITION OF FATTY ACID SYNTHASE AS A MEANS TO REDUCE ADIPOCYTE MASS

Weight loss was noted in nude mice treated with cerulenin, a non-competitive inhibitor of FAS. Sustained reduction of adipocyte mass in humans without toxicity would significantly impact disease prevention worldwide. Aside from psychological and self-este

Design, synthesis, and biological evaluation of a small-molecule inhibitor of the histone acetyltransferase Gcn5

HATs off! The development of the first cell-permeable small-molecule inhibitor of the human histone acetyltransferase (HAT) Gcn5 opens up new possibilities for understanding the histone code. Based on kinetic data and the proposed mechanism of the acetyla

Retroviral protease inhibitors

N-heterocyclic moiety-containing hydroxyethylamine protease inhibitor compounds, methods for making the compounds, and intermediates useful in the method. Also, a method for inhibiting retroviral proteases and for treatment or prophylaxis of a retroviral infection.

α-and β-amino acid hydroxyethlamino sulfonamides useful as retroviral protease inhibitors

α- and β-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.

alpha - and beta -amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

alpha - and beta -amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.

Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors

PCT No. PCT/US94/09139 Sec. 371 Date Jan. 24, 1996 Sec. 102(e) Date Jan. 24, 1996 PCT Filed Aug. 23, 1994 PCT Pub. No. WO95/06030 PCT Pub. Date Mar. 2, 1995The invention relates to sulfonamide-containing hydroxyethylamine protease inhibitor compounds, their process of making, composition and method of use for inhibiting retroviral proteases such as human immunodeficiency virus.

Alpha- and beta-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors

PCT No. PCT/US93/10552 Sec. 371 Date Feb. 2, 1995 Sec. 102(e) Date Feb. 2, 1995 PCT Filed Oct. 29, 1993 PCT Pub. No. WO94/10134 PCT Pub. Date May 11, 1994Certain Alpha- and Beta-amino acid hydroxyethylamino sulfamic acid derivatives represented by the following formula are useful as retroviral protease inhibitors:

β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

α- and β-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.